Predictive value of DOT1L mutations for clinical outcomes in non-small-cell lung cancer patients receiving immune checkpoint inhibitor therapy

Clin Transl Med. 2023 Oct;13(10):e1430. doi: 10.1002/ctm2.1430.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological* / pharmacology
  • Antineoplastic Agents, Immunological* / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation / genetics

Substances

  • Immune Checkpoint Inhibitors
  • Antineoplastic Agents, Immunological
  • DOT1L protein, human
  • Histone-Lysine N-Methyltransferase